Methods of treating obesity using a neurotensin receptor ligand
CA 2345180 A1 · Owner: Pfizer Products Inc. · Inventors: Hadcock, John Richard Neville
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to methods of treating obesity diabetes, sexual, dysfunction, atherosclerosis insulin resistance, impaired glucose tolerance hypercholesterolemia or hypertrigylceridemia using a neurotensin receptor ligand. The present invention also relates to pharmaceutical compositions and kits that, comprise a neurotensin receptor ligand.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 25, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 25, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 25, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.